You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel QcrB Inhibitors for the Treatment of Tuberculosis

    SBC: LGENIA INC.            Topic: NIAID

    Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents

    SBC: Grannus Therapeutics LLC            Topic: NCI

    Abstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Developing high throughput measurement of thiopurine in DNA by mass spectrometry

    SBC: Tymora Analytical Operations, LLC            Topic: 400

    PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)

    SBC: Tymora Analytical Operations, LLC            Topic: NIA

    PROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community

    SBC: EPERTURE LLC            Topic: NIA

    Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Drug target identification using CRISPRi/a screening

    SBC: BIOIO, LLC            Topic: 400

    ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Multi-Modal Venus Clot Removal Device

    SBC: Caeli Vascular LLC            Topic: NHLBI

    ABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Prevention of White Matter Injury in Premature Infants

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACTUp to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI) making it the most common form of brain injury affecting premature infants. PWMI is associated with significant morbidity, as affected individuals may have profound intellectual impairment and cerebral palsy. Highlighting the magnitude of PWMI, each year more than 400,000 infants ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government